tissue activator的例句大全

Comparison of thrombolytic therapy with recombinant tissue plasminogen activator and urokinase for acute myocardial infarction;

目的探讨静脉溶栓对男女急性心肌梗塞患者的疗效对比。

Comparison of Recombinant Tissue Plasminogen Activator, Urokinase and Defibrase in Vitro Simulation of Thrombolytic Test

重组织型纤溶酶原激活剂、尿激酶和降纤酶体外溶栓效果比较

Alterations in plasma levels of tissue plasminogen activator and its inhibitor after venous occlusion in normal subjects

正常人静脉血流阻断后血浆组织型纤溶酶原激活剂含量、活性及其抑制物活性的变化

Roles of tissue plasminogen activator in epidermal stratification

tPA对表皮角质形成细胞分层的影响

Treatment of intraocular fibrinous membrane by anterior chamber injection of tissue plasminogen activator after IOL implantation

t-PA前房注射治疗人工晶体植入术后纤维蛋白性膜

Objective To evaluate the effects of ultrasound irradiation on tissue plasminogen activator ( TPA) fibrinolysis in vitro.

目的评价在体外实验条件下，超声波辐照对组织型纤溶酶原激活物（TPA）溶栓效率的促进作用。

Construction of a Human Tissue-type Plasminogen Activator Tissue Specific Expression Vector and Establishment of Its Transgenic Mice

tPA乳腺组织特异性表达载体构建及转基因小鼠建立

Effect of mild hypothermia on the content of tissue-type plasminogen activator in retina tissue of rats with ischemia reperfusion injury

亚低温对缺血再灌注损伤大鼠视网膜组织型纤溶酶原激活物含量的影响

Objective To evaluate the clinical efficacy and safety of intravenous thrombolytic therapy using low dose recombinant tissue plasminogen activator ( r-TPA) and recombinant strepokinase ( r-SK) in patients with acute myocardial infarction ( AMI).

目的评价小剂量重组组织型纤溶酶原激活物（r-TPA）与国产重组链激酶（r-SK）治疗急性心肌梗死（AMI）的疗效，并比较二者的差异。

Establishment and Standardization of the National Reference Standard of Recombinant Human Tissue Plasminogen Activator

首批重组人组织纤溶酶原激活剂国家标准品的研制

The regulatory effect of tissue plasminogen activator involved in central nervous insult

组织型纤溶酶原激活物在中枢神经损伤中的调节作用

Clinical observation of treating intraocular hemorrhage with tissue plasminogen activator

t-PA治疗眼内出血的初步临床观察

Objective To observe the thrombolysis effects of recombinant human tissue type plasminogen activator ( Reteplase) on coronary artery thrombosis in dogs.

目的观察重组人组织型纤溶酶原激活剂缺失变体（reteplase）对犬冠状动脉血栓的溶栓作用。

There seems to be a strong association between CP and semen delayed liquefaction. Researches on the mechanism of semen delayed liquefaction resulting from CP mainly focus on the proteolytic ferment, plasminogen activator, prostate acid phosphatase, tissue factor, lack of zinc, and pH.

目前对CP所致精液延迟液化机制的研究主要集中在蛋白水解酶系、纤溶酶原激活因子系统和微量元素锌缺乏以及pH值改变等方面。

Commonly used thrombolytic drugs contant Streptokinase, Urokinase ( UK), Recombinant tissue type plasminogen activator ( rt-PA), Vermis kinase, Batroxobin, Reteplase etc, UK in especial.

常用的溶栓药物有：链激酶、尿激酶（urokinase，UK）、重组组织型纤溶酶原激活物（rt-PA）、蚓激酶、巴曲酶、瑞替普酶等，其中以UK最为常用。

Abstract We detected the changes of activities of tissue type plasminogen activator ( t PA) and its rapid inhibitor ( PAI 1) in plasma in the patients with migraine and tension type headache ( TTH) by chromophore substrate assay.

本研究应用发色底物法（CS）测定了两类原发性头痛：偏头痛及紧张性头痛患者血浆组织型纤溶酶原激活物（t－PA）及其快速抑制物（PAI－1）活性的变化规律。

Study on tissue plasminogen activator change in recurrence of stroke patients The blindness was secondary to embolic infarction of both occipital lobes developing as a sequela of IE.

血纤溶活性变化对缺血性脑梗死复发的影响眼盲次发于两侧脑枕叶血栓性梗塞，为感染性心内膜炎的并发症。

Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery

前房内注射组织纤溶酶原激活剂预防先天性白内障术后严重的纤维渗出

We detected plasma tissue plasminogen activator ( t-PA) and plasminogen activator Inhibitor ( PAI) activity in 52 patients with acute leukemia ( AL) by a chromogenic substrate method.

应用发色底物比色分析法，对42例正常人和52例急性白血病（AL）病人血浆组织纤溶酶原激活剂（t-PA）、组织纤溶酶原激活剂抑制剂（PAI）活性进行了检测。

A luminescence solid phase assay for tissue type plasminogen activator ( t-PA) was developed.

本文建立了组织型纤溶酶原激活剂（t-PA）活力的发光固相测定方法。